# Arcturus Therapeutics

Type: Company (ARCT)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/arcturus-therapeutics
Canonical HTML page: https://getfinancebrief.com/entity/arcturus-therapeutics

## Recent coverage (2 stories)

### Analyst Sentiment Shifts: Xponential Fitness Downgraded, Rocket Lab Initiated
2026-03-19 14:56:55 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A significant wave of analyst rating changes has hit the market, featuring a notable downgrade for boutique fitness giant Xponential Fitness and a bullish initiation for space leader Rocket Lab. These shifts underscore a broader institutional reassessment of growth trajectories across the fitness, aerospace, and biotechnology sectors.
Full story: https://getfinancebrief.com/story/analyst-sentiment-shifts-xponential-fitness-rocket-lab

### Biotech Execution in Focus: Arcturus and Rigel Set for Q4 Earnings Results
2026-03-02 22:55:18 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution. Investors are focused on Arcturus's mRNA vaccine rollout in Japan and Rigel's integration of its expanded oncology portfolio.
Full story: https://getfinancebrief.com/story/arcturus-rigel-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.